ATXS
Price
$12.80
Change
+$0.26 (+2.07%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
715.84M
49 days until earnings call
Intraday BUY SELL Signals
XENE
Price
$40.77
Change
-$0.81 (-1.95%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
3.21B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATXS vs XENE

Header iconATXS vs XENE Comparison
Open Charts ATXS vs XENEBanner chart's image
Astria Therapeutics
Price$12.80
Change+$0.26 (+2.07%)
Volume$11.09K
Capitalization715.84M
Xenon Pharmaceuticals
Price$40.77
Change-$0.81 (-1.95%)
Volume$24.35K
Capitalization3.21B
ATXS vs XENE Comparison Chart in %
View a ticker or compare two or three
VS
ATXS vs. XENE commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (ATXS: $12.54 vs. XENE: $41.58)
Brand notoriety: ATXS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 47% vs. XENE: 137%
Market capitalization -- ATXS: $731.26M vs. XENE: $3.15B
ATXS [@Biotechnology] is valued at $731.26M. XENE’s [@Biotechnology] market capitalization is $3.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 3 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 3 bearish.
  • XENE’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than XENE.

Price Growth

ATXS (@Biotechnology) experienced а -5.00% price change this week, while XENE (@Biotechnology) price change was -1.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

ATXS is expected to report earnings on Mar 05, 2026.

XENE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.21B) has a higher market cap than ATXS($716M). ATXS YTD gains are higher at: -4.202 vs. XENE (-7.229). ATXS has higher annual earnings (EBITDA): -136.51M vs. XENE (-338.18M). XENE has more cash in the bank: 462M vs. ATXS (228M). ATXS has less debt than XENE: ATXS (4.46M) vs XENE (8.33M). XENE has higher revenues than ATXS: XENE (7.5M) vs ATXS (706K).
ATXSXENEATXS / XENE
Capitalization716M3.21B22%
EBITDA-136.51M-338.18M40%
Gain YTD-4.202-7.22958%
P/E RatioN/AN/A-
Revenue706K7.5M9%
Total Cash228M462M49%
Total Debt4.46M8.33M54%
FUNDAMENTALS RATINGS
ATXS vs XENE: Fundamental Ratings
ATXS
XENE
OUTLOOK RATING
1..100
7570
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
9936
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
4057
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
8524

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (75) in the Biotechnology industry is in the same range as ATXS (77). This means that XENE’s stock grew similarly to ATXS’s over the last 12 months.

XENE's Profit vs Risk Rating (36) in the Biotechnology industry is somewhat better than the same rating for ATXS (99). This means that XENE’s stock grew somewhat faster than ATXS’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as ATXS (98). This means that XENE’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (40) in the Biotechnology industry is in the same range as XENE (57). This means that ATXS’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for ATXS (100). This means that XENE’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSXENE
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
61%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 25 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signal:
Gain/Loss:
XENE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIREX10.76N/A
N/A
Fidelity Intl Real Estate
RGEAX11.23-0.02
-0.18%
Russell Inv Global Equity A
RSGFX10.38-0.03
-0.29%
Victory RS Select Growth C
VHCOX98.04-0.39
-0.40%
Vanguard Capital Opportunity Inv
BIRAX23.66-0.17
-0.71%
BlackRock Sust Awr Advtg Lg Cp Cr Inv A

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with RGNX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+0.24%
RGNX - ATXS
48%
Loosely correlated
-0.66%
SYRE - ATXS
47%
Loosely correlated
+5.17%
XENE - ATXS
46%
Loosely correlated
+3.02%
ORKA - ATXS
46%
Loosely correlated
+2.11%
REPL - ATXS
44%
Loosely correlated
-4.10%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+3.02%
IDYA - XENE
57%
Loosely correlated
+5.53%
NUVL - XENE
57%
Loosely correlated
+6.59%
SGMO - XENE
53%
Loosely correlated
-3.43%
XNCR - XENE
52%
Loosely correlated
+3.66%
NRIX - XENE
51%
Loosely correlated
+0.58%
More